1. Home
  2. INDI vs ABUS Comparison

INDI vs ABUS Comparison

Compare INDI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INDI

indie Semiconductor Inc.

HOLD

Current Price

$4.06

Market Cap

906.0M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.28

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDI
ABUS
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.0M
848.8M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
INDI
ABUS
Price
$4.06
$4.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$6.25
$5.00
AVG Volume (30 Days)
5.7M
1.3M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
3.95
55.26
EPS
N/A
0.87
Revenue
$217,394,000.00
$14,083,000.00
Revenue This Year
$25.54
N/A
Revenue Next Year
$38.45
$239.71
P/E Ratio
N/A
$5.00
Revenue Growth
0.33
128.21
52 Week Low
$2.32
$3.04
52 Week High
$6.05
$5.10

Technical Indicators

Market Signals
Indicator
INDI
ABUS
Relative Strength Index (RSI) 43.21 44.01
Support Level $4.03 $4.16
Resistance Level $4.11 $4.63
Average True Range (ATR) 0.41 0.19
MACD -0.07 -0.02
Stochastic Oscillator 18.98 26.03

Price Performance

Historical Comparison
INDI
ABUS

About INDI indie Semiconductor Inc.

Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: